Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon May 03, 2022 8:33am
204 Views
Post# 34650423

RE:Finally! Easy to parse data!

RE:Finally! Easy to parse data!

The Best part is that in the Optimized group, they went from

April 5th:  at 180 days 40.7% CR and 18.5% PR= totals responders 59.2%

April 29  at 180 days  53% CR  and 24% PR= total responders 76%-77%

competition Vicinium was 28% CR at 180 days  we are double plus 24% PR who can possibly convert to CR and increase CR of 53% even more.  

Recent suggestions by bladder cancer experts suggest that new investigational agents for NMIBC should show at least 45% CR efficacy at 180 days in order to be cost effective vs Cystectomies, if I remember  I will post article if I find it.  It is great to see that data is improving, we need to maintain this trend from here on and eventually market will catch on.  IMHO 


DJDawg wrote:
The way they present the data in the MD and A is the way they should have presented it in the news release...and ever time before. Finally!

Here for ease of access

All and optimized

https://postimg.cc/cgj6nLHM

Evaluable

https://postimg.cc/cgj6nLHM



 

<< Previous
Bullboard Posts
Next >>